Clinical Research Directory
Browse clinical research sites, groups, and studies.
TumorGlow Intraoperative Molecular Imaging (IMI)
Sponsor: University of Pennsylvania
Summary
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.
Official title: A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2024-08-14
Completion Date
2027-01-14
Last Updated
2026-03-09
Healthy Volunteers
No
Conditions
Interventions
Indocyanine Green
The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Locations (1)
University of Pennsylvania
Philadelphia, Pennsylvania, United States